Home » Biotechnology »Commentaries »Health » Currently Reading:

Genetic Testing of Citizens Is a Backdoor into Total Population Surveillance by Governments and Companies

June 5, 2014 Biotechnology, Commentaries, Health No Comments

by Helen Wallace, GeneWatch UK

The new Chief Executive of the National Health Service (NHS) in England, Simon Stevens, was recently reported arguing that the NHS must be transformed to make people’s personal genetic information the basis of their treatments (1).

His proposition is unsurprising since it is in line with the efforts of successive UK governments to build a DNA database in the NHS in England by stealth. In particular, sequencing every baby at birth and storing whole genomes in electronic medical records is a plan backed by Health Secretary Jeremy Hunt (2). The current version of this plan would involve sharing whole or partial DNA sequences (genomes or genotypes) with companies like Google, which would use genetic information and health data to calculate personal risk assessments for feedback to patients (3). Massive investment from taxpayers would be required as part of a public-private partnership that would allow commercial exploitation of the data.

Building a DNA database within the NHS would be a massive waste of public money. But it would also create a system of total surveillance which would enable the government and private companies to track every individual, not to mention their relatives. This is not speculation; as wikileaks revealed, the United States government is already actively collecting DNA samples and biometric data on foreign officials and populations.

DNA

DNA (Credit Zephyris)

Commercial companies wish to exploit genetic information to market products such as drugs and supplements to healthy people, based on genetic risk assessments. If current trends continue, this will harm, not benefit, health: it is personalised marketing not personalised medicine. The potential for misuse is very high. Doctors could be replaced by computer algorithms used to market medication, massively expanding the drug market to include large numbers of healthy people, rather than smaller numbers of (often poorer) people who are sick. There is also the danger that prescribing would be driven by vested interests, rather than medical need: with high financial costs and more harmful side effects. Genetic risk assessments could also be misused, leading to stigma or discrimination, for example by insurers.

Why does the NHS want to collect genetic information?
There is one element of truth to Simon Stevens’ remarks. Some cancer drugs have been successfully tailored to genetic mutations that arise in the cancer tumour. However, attempts to select drugs for people based on the genetic make-up they are born with (their genome or genotype) have largely been a failure. This is because genetic differences only account for a part of individual differences in metabolism. For example, a recent study found that targeting warfarin treatment based on genetic make-up did not improve health outcomes, although this application was regarded as the ‘poster child’ of this approach (4).

Why did it not work? An important misconception, apparently shared by Simon Stevens, is that genes are good predictors of most diseases and adverse drug reactions in most people. However, contrary to misleading claims made to promote the Human Genome Project, this is not true (5). Moreover, even if it were true, there is no evidence that genetic selection of individuals, for example into high risk and low risk groups, improves outcomes or cuts costs. All of which begs the question of the purpose of taking and storing genetic information as a default medical procedure.

The online gene testing company 23andMe, funded by Google, has been forced to withdraw its gene tests from the US market due to failure to prove they can reliably predict individual risks of many common conditions using computer algorithms. The company now wants to target the UK market, where genetic testing is not regulated (6). Patrick Chung, a 23andMe board member and partner at the venture-capital firm NEA told Fast Company (7): “…23andMe will make money by partnering with countries that rely on a single-payer health system. “Let’s say you genotype everyone in Canada or the United Kingdom or Abu Dhabi,” he says, “and the government is able to identify those segments of the population that are most at risk for heart disease or breast cancer or Parkinson’s. You can target them with preventative messages, make sure they’re examined more frequently, and in the end live healthier lives, and the government will save massive expenses because they halted someone who’s prediabetic from getting diabetes. 23andMe has been in discussion with a bunch of such societies“. Yet there is not a scrap of evidence that this approach is good for health. This is because genomic tests have limited clinical validity or utility; so in reality there is no health benefit to targeting segments of the population in this way.

Genetic testing remains useful to diagnose rare genetic disorders, mainly in babies and young children, and whole genome sequencing has helped to identify new mutations causing these diseases. Rare familial (largely inherited) forms of many common diseases also exist, including breast cancer, but these account for only a small percentage of cases of these conditions.

Use of genetic testing in the NHS should focus on prioritising resources for the limited applications that do work, not on introducing misleading and harmful screening of the whole population and creating unnecessary, expensive databases. Certainly it should not be driven by ulterior commercial and government interests.

References

(1)   New NHS boss: service must become world leader in personalised medicine. The Guardian. 4th June 2014. http://www.theguardian.com/society/2014/jun/04/nhs-boss-world-leader-personalised-medicine

(2)   Children could have DNA tested at birth. The Telegraph. 8th December 2013. http://www.telegraph.co.uk/health/healthnews/10501788/Children-could-have-DNA-tested-at-birth.html

(3)   GeneWatch UK PR: GeneWatch UK report exposes plans to build a DNA database by stealth in the NHS. 23rd May 2013. http://www.genewatch.org/article.shtml?als[cid]=569352&als[itemid]=572536

(4)   Pharmacogenomic Warfarin Dosing: Worth the Cost? Medscape. 23rd December 2013. http://www.medscape.com/viewarticle/818088

(5)   Human Genetic Predispositions – the hidden politics of genomic science. Bioscience Resource Project. http://www.bioscienceresource.org/resources/human-genetic-predisposition/

(6)   Gene startup 23andme casts eyes abroad after U.S. regulatory hurdle. Reuters. 6th May 2014. http://in.reuters.com/article/2014/05/07/23andme-genetictesting-idINL2N0NT05I20140507

(7)   Inside 23andMe founder Anne Wojcicki’s $99 DNA Revolution. Fast Company. 14th October 2013. http://www.fastcompany.com/3018598/for-99-this-ceo-can-tell-you-what-might-kill-you-inside-23andme-founder-anne-wojcickis-dna-r

Dr Helen Wallace is Executive Director of GeneWatch UK

Comment on this Article:







Science News on the Web

Why Independent Science News?

Scientific inventions and ideas shape the future. As science becomes ever more beset by commercial and ideological pressures, there is urgent need for scientific reporting and analysis from an independent, expert, public interest perspective. With this standard, Independent Science News works to shape a future that is biodiverse, just, and healthy for everyone.
More about us...

Sign up to our mailing list

E-mail address:
Name (optional):

Related News Articles

New Research Links Neonicotinoid Pesticides to Monarch Butterfly Declines

EU Safety Institutions Caught Plotting an Industry “escape route” Around Looming Pesticide Ban

How “Extreme Levels” of Roundup in Food Became the Industry Norm

Can the Scientific Reputation of Pamela Ronald, Public Face of GMOs, Be Salvaged?

No Scientific Consensus on Safety of Genetically Modified Organisms

The Experiment Is on Us: Science of Animal Testing Thrown into Doubt

Psychiatrists plead to continue funding of genetic approaches to disease

23andMe disproves its own business model

Commentaries

Growing Doubt: a Scientist’s Experience of GMOs

Jonathan Latham

Jonathan R. Latham, PhD By training, I am a plant biologist. In the early 1990s I was busy making genetically modified plants (often called GMOs for Genetically Modified Organisms) as part of the research that led to my PhD. Into these plants we were putting DNA from various foreign organisms, …




Neoliberal Ebola: The Agroeconomic Origins of the Ebola Outbreak

Guinea Forest Region in 2014

by Rob Wallace The notion of a neoliberal Ebola is so beyond the pale as to send leading lights in ecology and health into apoplectic fits. Here’s one of bestseller David Quammen’s five tweets denouncing my hypothesis that neoliberalism drove the emergence of Ebola in West Africa. I’m an “addled …




Ruthless Power and Deleterious Politics: From DDT to Roundup

DDT, Time Magazine, 1947

By Evaggelos Vallianatos Morton Biskind, a physician from Westport, Connecticut, was a courageous man. At the peak of the cold war, in 1953, he complained of maladies afflicting both domestic animals and people for the first time. He concluded that the popular insect poison DDT was the agent of their …




Monsanto’s Worst Fear May Be Coming True

Chipotle Mexican Grill

by Jonathan Latham, PhD The decision of the Chipotle restaurant chain to make its product lines GMO-free is not most people’s idea of a world-historic event. Especially since Chipotle, by US standards, is not a huge operation. A clear sign that the move is significant, however, is that Chipotle’s decision …




More Commentaries...

Reviews

Poison Spring: The Secret History of Pollution and the EPA

Poison Spring Evaggelos Valllianatos

Book Author: Evaggelos Vallianatos with McKay Jenkins Reviewed by: Carol Van Strum “Science is the belief in the ignorance of experts,” Richard Feynman famously declared in 1966. Ever quick to challenge accepted wisdom, he distinguished the laudable ignorance of science, forever seeking unattainable certainties, from the dangerous ignorance of experts …




The Real Cost of Fracking: How America’s Shale Gas Boom Is Threatening Our Families, Pets, and Food

The Real Cost of Fracking book cover

Book Authors: Michelle Bamberger and Robert Oswald Reviewed by Allison Wilson (The Bioscience Resource Project) The first researchers to systematically document ill health in livestock, pets, and people living near fracking drill sites were Michelle Bamberger and Robert Oswald. Bamberger, a veterinarian, and Oswald, a professor of molecular medicine at …




More Reviews...

Show Buttons
Share On Facebook
Share On Twitter
Share On Google Plus
Hide Buttons